Guardant Health Q1 Revenue Rises 48% to $301.7M, Raises 2026 Guidance
GH•Guardant Health reported first-quarter revenue of $301.7 million, up 48% year-on-year, driven by oncology revenue of $205.0 million (+36%) on approximately 86,000 tests (+47%). The company also raised its full-year 2026 revenue guidance.
1. First-Quarter Financial Performance
Guardant Health delivered total revenue of $301.7 million for Q1 2026, marking a 48% increase from the prior year period. Oncology segment revenue reached $205.0 million, up 36%, supported by approximately 86,000 tests processed, a 47% volume gain.
2. Updated Full-Year Guidance
Reflecting the stronger-than-expected first-quarter results and sustained test volume acceleration, the company raised its full-year 2026 revenue guidance, underscoring confidence in ongoing market adoption of its precision oncology offerings.
